Daratumumab for hard-to-clear T-cell leukemia traces
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have T-cell acute lymphoblastic leukemia (T-cell ALL) that is in remission after chemotherapy (first or later remission), or almost in remission (CRi).
- Your leukemia trace level (MRD) is still present or has returned at a level of at least 1 in 10,000 (MRD ≥ 10^-4), confirmed by a central test using flow cytometry.
- You’ve had at least two blocks of intensive chemotherapy before starting this study.
- If you had a bone marrow transplant, you cannot have ongoing graft-versus-host disease (GVHD) that needs ongoing immune-suppressing medicines (small-dose prednisone up to 10 mg/day is allowed).
- Your strength and organs must meet lab/health thresholds (including neutrophils ≥ 750, platelets ≥ 75,000; and liver/kidney/bilirubin within set limits).
- If you could become pregnant or father a child, you must use reliable contraception (or not have sex) during the study and for 3 months after the last dose, and you must agree not to donate eggs/sperm during that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
This trial tests if adding a targeted drug called daratumumab to standard chemotherapy works better for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab helps the immune system find and attack cancer cells.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
This Phase 2 study tests whether adding daratumumab to standard chemotherapy, followed by a stem cell transplant, can improve outcomes in primary plasma cell leukemia. It aims to see how well this treatment works and whether it’s safe for people who are eligible for intensive therapy and transplant.
This trial tests a drug called isatuximab for people with a type of leukemia (T-cell acute lymphoblastic leukemia) that has come back after treatment or that did not go away. Isatuximab targets a protein on the leukemia cells, which might help the immune system fight the disease.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.